Astellas Pharma (Astellas Pharma) Additional Paid-In Capital : $1,271 Mil(As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Additional Paid-In Capital?

Astellas Pharma's quarterly additional paid-in capital declined from Jun. 2023 ($1,278 Mil) to Sep. 2023 ($1,232 Mil) but then increased from Sep. 2023 ($1,232 Mil) to Dec. 2023 ($1,271 Mil).

Astellas Pharma's annual additional paid-in capital declined from Mar. 2021 ($1,636 Mil) to Mar. 2022 ($1,514 Mil) and declined from Mar. 2022 ($1,514 Mil) to Mar. 2023 ($1,356 Mil).

Astellas Pharma Additional Paid-In Capital Historical Data

The historical data trend for Astellas Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Additional Paid-In Capital Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,595.23

1,648.65

1,635.98

1,513.50

1,356.23

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															1,338.56	1,356.23	1,277.89	1,232.02	1,270.88

Astellas Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Astellas Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.